Payment overview · 2025
General Payments
$2,202.11
114 reported records · 18 companies
Healthcare provider profile · identity verified
Delano Benjamin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FORESTDALE, AL · NPI 1184800948
Verified facts
What the public records show
CMS Open Payments records show Delano Benjamin, M.D. received $2,202.11 in general payments during 2025 across 114 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $321.45 | 14.6% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $296.73 | 13.5% | 16 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $274.12 | 12.4% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $222.95 | 10.1% | 11 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $166.17 | 7.5% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $132.73 | 6.0% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $129.02 | 5.9% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $124.31 | 5.7% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $116.43 | 5.3% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $83.06 | 3.8% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $72.44 | 3.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.90 | 2.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.72 | 2.4% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.05 | 2.0% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $40.38 | 1.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.79 | 1.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.12 | 1.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.74 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,190.82 | 113 |
| Education | $11.29 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $274.12 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $215.81 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $205.33 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $201.87 | 10 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $166.17 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $132.73 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $129.02 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $124.31 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $116.43 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $103.08 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $89.91 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $83.06 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $80.92 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $64.12 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.81 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $44.05 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $40.38 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.25 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.69 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.21 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 209 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 137 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 248 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 119 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
209 | 62 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
119 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
209 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
137 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
248 | 60 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
109 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 896 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 800 | 253 |
| Amlodipine Besylate | Amlodipine Besylate | 787 | 247 |
| Gabapentin | Gabapentin | 726 | 133 |
| Trazodone Hcl | Trazodone Hcl | 442 | 93 |
| Losartan Potassium | Losartan Potassium | 402 | 117 |
| Hydrochlorothiazide | Hydrochlorothiazide | 336 | 95 |
| Lisinopril | Lisinopril | 325 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 324 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 315 | 89 |
| Tizanidine Hcl | Tizanidine Hcl | 287 | 64 |
| Tramadol Hcl | Tramadol Hcl | 287 | 77 |
| Omeprazole | Omeprazole | 267 | 73 |
| Metformin Hcl | Metformin Hcl | 249 | 78 |
| Ozempic | Semaglutide | 248 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 239 | 76 |
| Pravastatin Sodium | Pravastatin Sodium | 231 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 226 | 70 |
| Furosemide | Furosemide | 222 | 70 |
| Jardiance | Empagliflozin | 209 | 62 |
| Potassium Chloride | Potassium Chloride | 208 | 67 |
| Famotidine | Famotidine | 206 | 60 |
| Clonazepam | Clonazepam | 205 | 27 |
| Glimepiride | Glimepiride | 203 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 202 | 26 |
| Lorazepam | Lorazepam | 195 | 37 |
| Meloxicam | Meloxicam | 184 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 182 | 55 |
| Montelukast Sodium | Montelukast Sodium | 180 | 56 |
| Sertraline Hcl | Sertraline Hcl | 173 | 39 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 163 | 25 |
| Alprazolam | Alprazolam | 160 | 21 |
| Pregabalin | Pregabalin | 154 | 27 |
| Allopurinol | Allopurinol | 140 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 140 | 29 |
| Celecoxib | Celecoxib | 137 | 45 |
| Mounjaro | Tirzepatide | 137 | 28 |
| Metformin Hcl Er | Metformin Hcl | 135 | 43 |
| Ibuprofen | Ibuprofen | 132 | 58 |
| Mirtazapine | Mirtazapine | 132 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 119 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 119 | 36 |
| Paroxetine Hcl | Paroxetine Hcl | 118 | 18 |
| Eliquis | Apixaban | 109 | 26 |
| Ibandronate Sodium | Ibandronate Sodium | 109 | 39 |
| Bupropion Xl | Bupropion Hcl | 106 | 31 |
| Carvedilol | Carvedilol | 106 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 34 |
| Methylprednisolone | Methylprednisolone | 103 | 87 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 36 |
| Buspirone Hcl | Buspirone Hcl | 98 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 88 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 84 | 41 |
| Chlorthalidone | Chlorthalidone | 83 | 25 |
| Simvastatin | Simvastatin | 82 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 78 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 27 |
| Prednisone | Prednisone | 74 | 37 |
| Clonidine Hcl | Clonidine Hcl | 73 | 13 |
| Ezetimibe | Ezetimibe | 73 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 72 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 67 | 26 |
| Topiramate | Topiramate | 66 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 13 |
| Alendronate Sodium | Alendronate Sodium | 59 | 18 |
| Olanzapine | Olanzapine | 59 | suppressed |
| Temazepam | Temazepam | 59 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 17 |
| Donepezil Hcl | Donepezil Hcl | 55 | 14 |
| Spironolactone | Spironolactone | 54 | 15 |
| Meclizine Hcl | Meclizine Hcl | 52 | 14 |
| Myrbetriq | Mirabegron | 52 | 17 |
| Nystatin | Nystatin | 52 | 24 |
| Lovastatin | Lovastatin | 51 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | 19 |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Atenolol | Atenolol | 44 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | 15 |
| Azithromycin | Azithromycin | 42 | 38 |
| Methocarbamol | Methocarbamol | 42 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 37 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | 13 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Naproxen | Naproxen | 34 | suppressed |
| Telmisartan | Telmisartan | 34 | 11 |
| Mupirocin | Mupirocin | 33 | 24 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 11 |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 11 |
| Ramipril | Ramipril | 28 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | 12 |
| Zaleplon | Zaleplon | 25 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | 11 |
| Fluconazole | Fluconazole | 23 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Dayvigo | Lemborexant | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Valproic Acid | Valproic Acid | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Felbamate | Felbamate | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,202.11 · 114 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, General - Pain Management, JARDIANCE, Kerendia, Korlym, MOUNJARO, NURTEC ODT, NUZYRA, Ozempic, PAXLOVID, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XHANCE, XYOSTED, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error